In accordance with the Novation Agreement,
Velphoro® (Sucroferric Oxyhydroxide Chewable Tablets )
As of
Velphoro® is a Class 5.1 imported innovative drug, which was approved through the priority review and approval procedure in
Hyperphosphatemia is a common complication in CKD patients, especially in patients with end-stage renal disease on dialysis, characterized by a high morbidity and a low compliance rate. It is an independent risk factor for nephropathy progression, secondary hyperparathyroidism, cardiovascular events and all-cause mortality in CKD patients2. Controlling sP levels can significantly improve the outcomes of CKD patients.
Since non-calcium PB has no risk of vascular calcification, domestic and foreign guidelines consistently recommend non-calcium PB as first-line treatment for reducing sP levels, and limit the use of calcium-based PB. Velphoro® is a new generation of iron-based, non-calcium PB, reducing sP levels of patients and increasing the sP compliance rate. Velphoro® has been launched in 51 countries/territories including the US, EU and
It is demonstrated in multiple global clinical studies and real-world research data (as published in academic journals including International Urology and Nephrology, and Clinical Nephrology) and the Chinese instruction of the Product that compared with other PBs, patients maintained on Velphoro® used about 50% fewer PB pills/day3, and the proportion of patients achieving target sP increased by 95%4. Velphoro® has characteristics of good safety5 and patient compliance6 without risk of calcium and heavy metal accumulation. In addition, the Product holds the advantages of unaffected absorption of oral liposoluble vitamin D7, maintaining stable iron parameters8, improving the nutritional status in patients9, reducing hospitalization rates, and alleviating patients' medical financial burdens10. Velphoro® is expected to further improve the dialysis patients’ quality of life and become a new option of phosphorus-lowering treatment for CKD dialysis patients in
CMS continues to invest in and develop differentiated innovative products, providing a continuous source of momentum for the long-term and stable development of the Group. Velphoro® is a newly approved innovative drug in
More information about Hyperphosphatemia
The total number of CKD patients reaches 132 million in
Reference:
- Drug registration information can be found on the NMPA official website, as follows: https://www.nmpa.gov.cn/datasearch/search-result.html
Or can be found in the public medical insurance materials, as follows:
http://www.nhsa.gov.cn/attach/Ypsn2023/YPSW202300180/YPSW202300180-W1(ppt).pdf
- XQ Yu, et al. Chin J Nephrol, 2018. 34(11): 867-871
- The Instructions for Sucrose HydroxyIron Oxide Chewable Tablets
- Coyne DW, et al. Clin Nephrol. 2017 Aug;88(8):59-67.
- Xie, D., Ye, N. & Li, M., Int Urol Nephrol 50, 905-909 (2018)
- Floege J, et al. Nephrol Dial Transplant. 2015 Jun;30(6):1037-46
- Sprague SM,et al.Am J Nephrol. 2016;44(2)104-12
- Vervloet MG et al.
Clin Kidney J 2021;14:1770-9 - Kalantar-Zadeh K, et al. BMC Nephrol . 2019 0ct 29;20(1):396
- Kidney Med. 2020 May-Jun; 2(3): 307-316
- The data of China’s CNRDS reported by academician,
Meixiang Chen ., on 2023 Annual Conference ofChinese Nephrologist Association . - YF Chen, et al. Chin J Blood Purif. 2022; 21(05): 305-308.
- Kidney International Supplements, 2020, 10(2): e97–185
- Hong, D. et al. Sci Rep 12, 16694 (2022).
1. This news/article is intended to share cutting-edge medical information. It is only for reference by medical and health professionals for academic purposes and is not for advertising purposes; it does not recommend any drugs, medical devices and/or indications.
2. The information involved in this news/article is for reference only. Please follow the advice or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient's specific circumstances and in accordance with the drug package insert.
Media Contact
Brand:
Contact: CMS Investor Relations
Email: ir@cms.net.cn
Website: https://web.cms.net.cn/en/home/
Source:
Source:
2024 GlobeNewswire, Inc., source